Burning Rock Biotech Receives Nasdaq Minimum Bid Price Non-Compliance Notice
Ticker: BNR · Form: 6-K · Filed: Jan 4, 2024 · CIK: 1792267
Complexity: simple
Sentiment: bearish
Topics: delisting-risk, compliance-issue, nasdaq-rules
TL;DR
**Burning Rock Biotech got a Nasdaq delisting warning for its stock trading under $1.00.**
AI Summary
Burning Rock Biotech Ltd. (NASDAQ: BNR) received a notification from Nasdaq on December 29, 2023, stating that its American depositary shares (ADSs) traded below the minimum bid price of US$1.00 for 30 consecutive business days. This triggers a compliance period, but currently has no immediate impact on the trading of BNR shares. Investors should be aware that if the company fails to regain compliance, its shares could face delisting from Nasdaq, which would significantly reduce liquidity and potentially depress the stock price.
Why It Matters
This matters because if Burning Rock Biotech cannot get its stock price back above $1.00, its shares could be delisted from Nasdaq, making them harder to trade and potentially causing their value to drop significantly.
Risk Assessment
Risk Level: high — The company faces a significant risk of delisting if it cannot meet Nasdaq's minimum bid price requirement, which could severely impact its stock's liquidity and value.
Analyst Insight
A smart investor would closely monitor Burning Rock Biotech's stock price and any announcements regarding its plan to regain Nasdaq compliance. This situation introduces significant risk, and new investments should be approached with extreme caution until the delisting threat is resolved.
Key Numbers
- US$1.00 — Minimum Bid Price (The threshold Burning Rock Biotech's ADSs must meet to comply with Nasdaq listing rules.)
- 30 — Consecutive Business Days (The period for which Burning Rock Biotech's ADSs traded below the minimum bid price, triggering the Nasdaq notification.)
Key Players & Entities
- Burning Rock Biotech Limited (company) — the registrant and company receiving the Nasdaq notification
- NASDAQ (company) — the stock exchange that issued the notification
- Leo Li (person) — Chief Financial Officer who signed the 6-K filing
- US$1.00 (dollar_amount) — the minimum bid price requirement set by NASDAQ Listing Rule 5450(a)(1)
- December 29, 2023 (date) — date of the written notification from Nasdaq
- January 4, 2024 (date) — date the 6-K filing was signed and announced
Forward-Looking Statements
- Burning Rock Biotech will implement a strategy to increase its share price above $1.00 within the compliance period. (Burning Rock Biotech Limited) — medium confidence, target: Within the Nasdaq compliance period (typically 180 days)
- The company's stock price will remain volatile due to delisting concerns. (Burning Rock Biotech Limited) — high confidence, target: Next 6 months
FAQ
What is the specific reason Burning Rock Biotech received a notification from Nasdaq?
Burning Rock Biotech received a notification because its American depositary shares (ADSs) had a closing bid price below the minimum bid price of US$1.00 per share for 30 consecutive business days, as required by NASDAQ Listing Rule 5450(a)(1).
When did Burning Rock Biotech receive this notification from Nasdaq?
Burning Rock Biotech received the written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023.
Does this Nasdaq notification immediately affect the trading of Burning Rock Biotech's securities?
No, the filing explicitly states that the NASDAQ notification letter has no current effect on the listing or trading of the Company's securities on NASDAQ.
Who signed this 6-K filing on behalf of Burning Rock Biotech Limited?
The 6-K filing was signed by Leo Li, the Chief Financial Officer of Burning Rock Biotech Limited, on January 4, 2024.
What Nasdaq rule is Burning Rock Biotech currently not in compliance with?
Burning Rock Biotech is not in compliance with NASDAQ Listing Rule 5450(a)(1), which sets the minimum bid price requirement of US$1.00 per share.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-01-04 06:01:49
Filing Documents
- d657867d6k.htm (6-K) — 9KB
- d657867dex991.htm (EX-99.1) — 6KB
- 0001193125-24-001713.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Burning Rock Biotech Limited By: /s/ Leo Li Name: Leo Li Title: Chief Financial Officer Date: January 4, 2024 3